Cronos Group Inc Dossier - Source-backed chat

Cronos Group Inc

CRONNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.19

Intrinsic Value $3.16median of 3 methodsbased on filings through 30 Jun 2026

Market Price $3.21Price as of 1 Oct 2026

Near fair valueIntrinsic value is 1% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.2B

Enterprise Value $715.6M

Shares Outstanding 377.7M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cronos Group Inc. represents a unique, low-risk vehicle to play the global cannabis sector. Unlike its highly leveraged and dilutive Canadian peers, Cronos boasts a fortress-like balance sheet with $821.9 million in cash and virtually no debt, backed by tobacco giant Altria. The company has successfully transitioned to positive Adjusted EBITDA ($5.1 million in Q1 2026) and is demonstrating strong operational momentum, including achieving the #1 vape brand position in Canada and maintaining market leadership in Israel. With a market cap of approximately $1.03 billion, the enterprise is trading near its cash value, providing a massive margin of safety while offering significant optionality from European expansion (via the pending CanAdelaar acquisition) and potential U.S. federal legalization.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.53

Mean target$2.53

High · most bullish analyst$2.53

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5320%

Regulatory delays stall the CanAdelaar acquisition beyond the September 2026 long-stop date, and U.S. federal reform faces political gridlock. Intense price compression in Canada and geopolitical disruptions in Israel erode gross margins, pushing Adjusted EBITDA back into negative territory and forcing the company to burn through its cash reserves.

Base CaseCentral scenario

$2.5350%

Matches the consensus mean

Cronos continues to execute its asset-light, borderless product strategy, maintaining its #1 vape and edible positions in Canada and medical leadership in Israel. The company achieves steady, moderate revenue growth and remains Adjusted EBITDA positive. Capital is returned to shareholders via the authorized $50 million share repurchase program, and the cash pile is preserved to maintain a strong valuation floor.

Bull CaseUpside scenario

$2.5330%

U.S. federal rescheduling to Schedule III occurs rapidly, prompting Altria to deepen its partnership or fully acquire Cronos to lead its North American cannabis strategy. Simultaneously, the CanAdelaar acquisition closes smoothly, positioning Cronos as a dominant early-mover in the European adult-use market. Canadian and Israeli operations continue to expand margins through genetic innovation and GrowCo facility efficiencies, driving substantial net income growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Fortress balance sheet with $821.9 million in cash and cash equivalents and no external debt, providing unmatched downside protection.
Strategic backing and alignment with Altria Group, offering deep regulatory, marketing, and operational expertise.
Proven brand equity with Spinach holding the #1 vape and edible market share in Canada, and PEACE NATURALS leading the Israeli medical market.
Transition to operational profitability with positive Adjusted EBITDA of $5.1 million in Q1 2026.
Active capital return program with a newly authorized $50 million share repurchase program running through May 2027.

Key Investment Risks

Highly dependent on unpredictable regulatory frameworks across Canada, Israel, Germany, and the United States.
Severe price compression and intense competition in the Canadian adult-use market.
Geopolitical and security risks in Israel that could disrupt local operations and supply chains.
M&A execution risks associated with the pending acquisition of CanAdelaar B.V. in the Netherlands.

Thesis Invalidation Triggers

A material reversal in Adjusted EBITDA back to significant negative losses over consecutive quarters.
Failure to close the CanAdelaar acquisition by the September 9, 2026 deadline due to regulatory rejection.
Altria Group divesting its stake or terminating its strategic voting agreement with Cronos.
A major regulatory crackdown or rollback of cannabis liberalization policies in key operating markets.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.